Table 3.
Gene mutation features of 14 BCORMUT patients who accepted decitabine induction
| Case no | Class | Cycles* | Response | BCOR mutations (VAF) | Concomitant mutations |
|---|---|---|---|---|---|
| 1 | RAEB-t | 2 | CR | BCOR/4/C925Y (51%) | DHX9; WT1 |
| 2 | RAEB1 | 6 | CR | BCOR/11/K1452X (60%) | DNMT3A; ROBO1; STAG2 |
| 3 | RAEB2 | 4 | CR | BCOR/8/R1323W (50%) | NPM1 |
| 4 | CMML1 | 3 | CR | BCOR/8/K1339N (33%) | ASXL1; MPL; TET2; UPF3A |
| 5 | RAEB1 | 4 | mCR + HI | BCOR/4/A619fs (16%) | PHF6; RUNX1; TET2 |
| 6 | RCMD | 3 | CR | BCOR/4/Y361fs (85%) | NRAS; ROBO1; RUNX1; U2AF1 |
| 7 | RCMD | 4 | CR | BCOR/12/R1547*(49%) | ASXL1; RUNX1; SRSF2 |
| 8 | RAEB1 | 4 | mCR | BCOR/4/p819-819del (74%) | DNMT3A; IDH2; ROBO1; RUNX1 |
| 9 | RAEB2 | 4 | CR | BCOR/7/R1165X (29%)/11/C4326 + 1C > A (56%) | CEBPA; DNMT3A; RUNX1; STAG2;TET2; U2AF1 |
| 10 | RAEB2 | 4 | NR | BCOR/7/P1101fs (65%) | ITIH3 |
| 11 | RAEB2 | 4 | CR | BCOR/4/V912fs (32%) | ASXL1; STAG2 |
| 12 | RCMD | 2 | NR | BCOR/4/P483L (48%) | DHX9; EZH2; IDH1; U2AF1 |
| 13 | RAEB2 | 4 | mCR + HI | BCOR/4/T738fs (46%) | EZH2; MPL; RUNX1 |
| 14 | CMML2 | 2 | NR | BCOR/4/P483L (100%) | None |
*The induced decitabine cycles number means the course number of continuously accepted decitabine treatment (the durations between courses did not exceed 30 days); For the CR achieved patients with less than 4 induced courses. (No. 1, 4 and 6), the patients rejected continuously decitabine usage by themselves